« Have The Rules Changed? |
Main
| Access to Phase I Drugs: A Constitutional Right? »
May 3, 2006
Full Disclosure
Posted by Derek
Since I made a big point out of this in a comment to the last Ariad post, I wanted to update things. The jury is out - literally - on the case versus Lilly right now, and I notice the stock creeping up a bit today.
So, I am now short Ariad stock, 1000 shares at 5.56. This isn't a recommendation that anyone else should run out and do the same, but I thought it was important that I mention it since I've written about the company. I'll post again on the topic after the verdict comes in (which will be when I close out this position, one way or another, I should think).
Comments (2)
+ TrackBacks (0) | Category: Business and Markets | Patents and IP
POST A COMMENT
- RELATED ENTRIES
- › Academia and Industry, Suing Each Other
- › Let's Start Off the Meeting With An Ad, OK?
- › The Academic-Industrial Collaboration in Drug Discovery Panel: Today
- › Glass Structure, Atom by Atom
- › How the Andrulis Paper Got Published
- › AstraZeneca in Waltham
- › Fluorine NMR: Why Not?
- › AstraZeneca Layoffs and Closings
1. Jake on May 4, 2006 1:58 PM writes...
Ariad won. Hope you didn't cover right away. And I also hope it'll get overturned.
Permalink to Comment2. Jonathan Robinson on May 5, 2006 8:19 PM writes...
I agree with your positioning on ARIA eventually winning the lawsuit (very slim) but be careful here as the other work the company is doing is probably worth something close to current value and if something good happens there, the stock could to up even with a loss. The mkt has to be factoring in very little value for a win here, unless Wall Street is more stupid than any of us believe. I have not seen one informed person believe that ARIA can eventually win. But what do I know, RIMM ultimately got held up in tech land.
Jon
Permalink to Comment